Diagnosis and treatment of diffuse large B-cell lymphoma
U Mey, F Hitz, A Lohri, S Pederiva, C Taverna… - Swiss medical …, 2012 - zora.uzh.ch
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant
lymphoma in the Western world. It has an aggressive natural history, with a median survival …
lymphoma in the Western world. It has an aggressive natural history, with a median survival …
Current treatment approaches for diffuse large B-cell lymphoma
T Illidge, S Tolan - Leukemia & lymphoma, 2008 - Taylor & Francis
There have been two major developments over the last decade that has led to
improvements in outcome and longer survival for patients with diffuse large B-cell lymphoma …
improvements in outcome and longer survival for patients with diffuse large B-cell lymphoma …
Standard treatment of advanced-stage diffuse large B-cell lymphoma
B Coiffier - Seminars in hematology, 2006 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized
in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic …
in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic …
Management of diffuse large B-cell lymphoma (DLBCL)
B Kubuschok, G Held, M Pfreundschuh - Non-Hodgkin Lymphoma …, 2015 - Springer
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. While
CHOP was the standard combination chemotherapy for 25 years, the incorporation of the …
CHOP was the standard combination chemotherapy for 25 years, the incorporation of the …
Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
R Sinha, LJ Nastoupil, CR Flowers - Blood and lymphatic cancer …, 2012 - Taylor & Francis
Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the
Western world. DLBCLs are clinically, biologically, and pathologically heterogeneous with …
Western world. DLBCLs are clinically, biologically, and pathologically heterogeneous with …
[HTML][HTML] Post relapse survival rates in diffuse large B-cell lymphoma
A McMillan, A Martín, C Haioun, A Chiappella… - Blood, 2016 - Elsevier
INTRODUCTION Diffuse large B-cell lymphoma (DLBCL) is the most frequently observed
hematologic malignancy with 45,000 patients newly diagnosed globally each year. DLBCL …
hematologic malignancy with 45,000 patients newly diagnosed globally each year. DLBCL …
Accelerated therapeutic progress in diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma in the
world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a …
world. Clinically, biologically, and pathologically, DLBCL is a heterogeneous entity with a …
[HTML][HTML] Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
M Horvat, V Zadnik, T Južnič Šetina… - Oncology …, 2018 - spandidos-publications.com
Abstract Treatment with rituximab plus a regimen of cyclophosphamide, doxorubicin,
vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma …
vincristine and prednisolone (CHOP) for patients with diffuse large B-cell lymphoma …
Current treatment strategy of diffuse large B-cell lymphomas
N Niitsu - International journal of hematology, 2010 - Springer
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma,
accounting for approximately 25–30% of all new patients. Rituximab, a genetically …
accounting for approximately 25–30% of all new patients. Rituximab, a genetically …
Diffuse large B-cell lymphoma
AK Ng - Seminars in Radiation Oncology, 2007 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-
Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients …
Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients …